Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06750484 · ClinicalTrials.gov registry record · Phase 2
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
A Phase 2 study of Breast Cancer Metastatic, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT06750484 is a Phase 2 study of Breast Cancer Metastatic that is actively recruiting participants, run by Yale University. The registered enrollment target is 40 participants, below the 90-participant average among 17 other Breast Cancer Metastatic trials with a reported enrollment target (56% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06750484, a Phase 2 study of Breast Cancer Metastatic, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to test the good and bad effects of a drug called trastuzumab deruxtecan (T-DXd) in adult patients with metastatic HER2-negative breast cancer and which patients might benefit the most from T-DXd.
Conditions Studied
Interventions
- DRUG Trastuzumab Deruxtecan
Study Locations (2)
Connecticut
- Yale University - New Haven
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-06-20 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06750484
The ClinicalTrials.gov registry entry for NCT06750484 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90-participant average among 17 other Breast Cancer Metastatic trials with a reported enrollment target (56% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer Metastatic appearing as the primary indexed condition, and to 1 intervention - of which Trastuzumab Deruxtecan is the first listed.
NCT06750484 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Connecticut, New York.
Frequently Asked Questions
What is clinical trial NCT06750484 about?
NCT06750484 is a clinical study titled "Trial of Trastuzumab Deruxtecan in Previously Treated HER2". The purpose of this study is to test the good and bad effects of a drug called trastuzumab deruxtecan (T-DXd) in adult patients with metastatic HER2-negative breast cancer and which patients might benefit the most from T-DXd.
What is the current status of trial NCT06750484?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-06-20. Estimated completion is 2028-12-31.
What conditions does trial NCT06750484 study?
This clinical trial studies the following conditions: Breast Cancer Metastatic.
What interventions are being tested in trial NCT06750484?
The interventions under investigation include: Trastuzumab Deruxtecan (DRUG).
Who is sponsoring clinical trial NCT06750484?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06750484 being conducted?
This trial has 2 study locations across Connecticut, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
ACTIVE NOT RECRUITING · Phase 2
-
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
COMPLETED · Phase 2
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
Nutrition Awareness Among Women With Non-Metastatic Breast Cancer
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.